nach oben

Supportive Care in Cancer

Erschienen in:

06.05.2019 | Review Article

Pharmacological evidence of medicinal cannabis in oncology: a systematic review

verfasst von: Danielle Brown, Michael Watson, Janet Schloss

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This systematic literature review examines research into the use of medicinal cannabis in cancer management. The aim was to identify the gaps in knowledge on the dose, dosing schedule and absorption of the administration routes of medicinal cannabis use in oncology.

Methods

A comprehensive search of the literature was conducted across six databases to identify original data reporting the pharmacology of medicinal cannabis in oncology.

Results

Eighteen articles were selected for review. Of the selected articles, ten were identified as randomised control trials, two experimental studies, two retrospective cohort studies and four case studies. Four articles reported absorption data and one drug interaction study was identified.

Conclusions

There is little evidence reported in the literature on the absorption of medicinal cannabis in cancer populations. Various reasons are explored for the lack of pharmacokinetic studies for medicinal cannabis in cancer populations, including the availability of assays to accurately assess cannabinoid levels, lack of clinical biomarkers and patient enrolment for pharmacokinetic studies.

Bridgeman MB, Abazia DT (2017) Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharmacy Ther 42(3):180–188

Russo EB, Marcu J (2017) Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol 80:67–134PubMedCrossRef

Mechoulam R, Cannabinoids as Therapeutic Agents (1986) The pharmacohistory of cannabis sativa. CRC-Press

Upton, R. American herbal pharmacopoeia®. 2017

Bogdanović V, Mrđanović J, Borišev I (2017) A review of the therapeutic antitumor potential of cannabinoids, vol 23

Guzman M et al (2006) A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95(2):197–203PubMedPubMedCentralCrossRef

Śledziński P, Zeyland J, Słomski R, Nowak A (2018) The current state and future perspectives of cannabinoids in cancer biology. Cancer Med 7(3):765–775PubMedPubMedCentralCrossRef

Nabissi M, Morelli MB, Offidani M, Amantini C, Gentili S, Soriani A, Cardinali C, Leoni P, Santoni G (2016) Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget 7(47):77543–77557PubMedPubMedCentralCrossRef

Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, Barcia J, Guzman M, Velasco G (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10(1):90–103PubMedCrossRef

10.

Liu WM, Scott KA, Shamash J, Joel S, Powles TB (2008) Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma 49(9):1800–1809

11.

Scott KA, Shah S, Dalgleish AG, Liu WM (2013) Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. Anticancer Res 33(10):4373–4380PubMed

12.

International Agency for Research on Cancer (2014) World cancer report. World Health Organisation, Lyon

13.

MacCallum CA, Russo EB (2018) Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 49:12–19PubMedCrossRef

14.

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564PubMedCrossRef

15.

Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61–65PubMedCrossRef

16.

Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86(8):1646–1647CrossRef

17.

Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163(7):1344–1364PubMedPubMedCentralCrossRef

18.

Zábranský, T., L. Hanuš, and R. Rokyta, Review of contemporary knowledge of the treatment effects of cannabis and related products and its outlook. 2017

19.

Murillo-Rodríguez E (2017) The endocannabinoid system : genetics, biochemistry, brain disorders, and therapy. Elsevier Science, San Diego

20.

Sharma P, Murthy P, Bharath MMS (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 7(4):149–156PubMedPubMedCentral

21.

Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4(8):1770–1804PubMedPubMedCentralCrossRef

22.

Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42(4):327–360PubMedCrossRef

23.

Turgeman I, Bar-Sela G (2017) Cannabis use in palliative oncology: a review of the evidence for popular indications. Israel Med Assoc J 19(2):85–88

24.

Tateo S (2017) State of the evidence: cannabinoids and cancer pain-a systematic review. J Am Assoc Nurse Pract 29(2):94–103PubMed

25.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 3(3):e123–e130PubMedPubMedCentral

26.

Reid R et al (2016) Complementary medicine use by the Australian population: a critical mixed studies systematic review of utilisation, perceptions and factors associated with use, vol 16

27.

Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, MP-F LK (2017) Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs Institute Reviewer’s Manual

28.

Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L (2017) Chapter 3: Systematic reviews of effectiveness. Joanna Briggs Institute Reviewer’s Manual

29.

Engels FK, de Jong FA, Sparreboom A, Mathot RAA, Loos WJ, Kitzen JJEM, de Bruijn P, Verweij J, Mathijssen RHJ (2007) Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12(3):291–300PubMedCrossRef

30.

Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70(5):656–663PubMedPubMedCentralCrossRef

31.

Strasser F et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394–3400. https://doi.org/10.1200/JCO.2005.05.1847 PubMedCrossRef

32.

Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, Baracos VE, Wismer WV (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22(9):2086–2093PubMedCrossRef

33.

Cote M et al (2016) Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol 125(4):317–324PubMedCrossRef

34.

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag 39(2):167–179CrossRef

35.

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT (2013) An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag 46(2):207–218CrossRef

36.

Lynch M, Cesar-Rittenberg P, Hohmann A (2014) A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manag 47:166–173. https://doi.org/10.1016/j.jpainsymman.2013.02.018 CrossRef

37.

Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449PubMedCrossRef

38.

Foroughi M, Hendson G, Sargent MA, Steinbok P (2011) Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas--possible role of Cannabis inhalation. Childs Nerv Syst 27(4):671–679CrossRefPubMed

39.

Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23(3):533–543PubMedCrossRef

40.

Elder JJ, Knoderer HM (2015) Characterization of dronabinol usage in a pediatric oncology population. J Pediatr Pharmacol Ther 20(6):462–467PubMedPubMedCentral

41.

Hernandez SL, Sheyner I, Stover KT, Stewart JT (2015) Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Care 32(1):5–7PubMedCrossRef

42.

Singh Y, Bali C (2013) Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol 6(3):585–592PubMedPubMedCentralCrossRef

43.

Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, Klimberg VS (2006) Prevention of nausea and vomiting following breast surgery. Am J Surg 191(6):767–772PubMedCrossRef

44.

Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol 20(2):567–573PubMedCrossRef

45.

Maida V (2008) Nabilone for the treatment of paraneoplastic night sweats: a report of four cases. J Palliat Med 11(6):929–934PubMedCrossRef

46.

Ursino M, Zohar S, Lentz F, Alberti C, Friede T, Stallard N, Comets E (2017) Dose-finding methods for phase I clinical trials using pharmacokinetics in small populations. Biom J 59(4):804–825PubMedPubMedCentralCrossRef

47.

Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46(1):86–95PubMedCrossRef

48.

Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, di Virgilio D, McArthur JW, Cheng YK, Hennig IM, Barrett DA, Fischer PM, Constantinescu CS, Gershkovich P (2017) Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep 7(1):14542PubMedPubMedCentralCrossRef

49.

Hryhorowicz S et al (2017) Pharmacogenetics of cannabinoids. Eur J Drug Metab Pharmacokinet:1–12

50.

Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ (2017) Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol 41(2):83–99PubMedPubMedCentralCrossRef

51.

Schwope DM, Scheidweiler KB, Huestis MA (2011) Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 401(4):1273–1283PubMedPubMedCentralCrossRef

52.

Lee D, Huestis MA (2014) Current knowledge on cannabinoids in oral fluid. Drug Test Anal 6(1–2):88–111PubMedCrossRef

53.

Comets E, Zohar S (2009) A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology. Clin Pharmacokinet 48(6):387–395PubMedPubMedCentralCrossRef

54.

Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F (2013) The medicinal use of Cannabis and cannabinoids—an international cross-sectional survey on administration forms. J Psychoactive Drugs 45(3):199–210PubMedCrossRef

55.

AbbVie Inc (2017) Full prescribing information for MARINOL capsules. Available from: http://www.rxabbvie.com/pdf/marinol_PI.pdf. Accessed 4 Nov 2017

56.

GW Pharma Ltd (2015) Sativex Oromucosal Spray. Available from: http://www.medicines.org.uk/emc/medicine/23262. Accessed 4 Nov 2017

57.

Ramer R, Hinz B (2017) Cannabinoids as anticancer drugs. Adv Pharmacol

58.

Nasir B et al (2017) Cannabis: a prehistoric remedy for the deficits of existing and emerging anticancer therapies. J Exploratory Res Pharmacol 2(3):93–104CrossRef

59.

Sanchez-Ramos J (2015) The entourage effect of the phytocannabinoids. Ann Neurol 77(6):1083–1083PubMedCrossRef

60.

Lewis MA, Russo EB, Smith KM (2018) Pharmacological foundations of cannabis chemovars. Planta Med 84(04):225–233PubMedCrossRef

61.

Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I, Eleni Anagnostou M, Babatunde F, Corazzari M, Redfern CPF, Velasco G, Lovat PE (2015) Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol 135(6):1629–1637PubMedCrossRef

62.

Romano B, Borrelli F, Pagano E, Cascio MG, Pertwee RG, Izzo AA (2014) Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine 21(5):631–639PubMedCrossRef

63.

Piomelli D, Russo EB (2016) The cannabis sativa versus Cannabis indica debate: an interview with Ethan Russo, MD. Cannabis Cannabinoid Res 1(1):44–46PubMedPubMedCentralCrossRef

64.

Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, Ricci-Vitiani L, Pallini R, Santoni G (2015) Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int J Cancer 137(8):1855–1869PubMedCrossRef

65.

Nabissi M, Morelli MB, Santoni M, Santoni G (2013) Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34(1):48–57PubMedCrossRef

66.

Scott KA, Dalgleish AG, Liu WM (2014) The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 13(12):2955–2967PubMedCrossRef

67.

Scott KA et al (2015) Inhibiting heat shock proteins can potentiate the cytotoxic effect of cannabidiol in human glioma cells. Anticancer Res 35(11):5827–5837PubMed

Titel: Pharmacological evidence of medicinal cannabis in oncology: a systematic review
verfasst von: Danielle Brown
Michael Watson
Janet Schloss
Publikationsdatum: 06.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 9/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04774-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Pharmacological evidence of medicinal cannabis in oncology: a systematic review

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Management of anticoagulation in patients with metastatic castration–resistant prostate cancer receiving abiraterone + prednisone

Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study

Patient perspectives on adapting meaning-centered psychotherapy in advanced cancer for the Chinese immigrant population

Neuropathic symptoms, physical and emotional well-being, and quality of life at the end of life

Need and demand for nutritional counselling and their association with quality of life, nutritional status and eating-related distress among patients with cancer receiving outpatient chemotherapy: a cross-sectional study

Effects of herbal medicine for xerostomia in head and neck cancer patients: an observational study in a tertiary cancer hospital

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie